Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVIGORATE-1: Secukinumab IV in Active Axial Spondyloarthritis
NCT04156620Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2019
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) comparing Secukinumab IV with Placebo / Secukinumab IV (2 arms). Primary endpoint: Assessment of SpondyloArthritis International Society 40 Response at 16 weeks. Started Dec 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT04156620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156620.